Gene silencing approaches against each amyloidogenic protein used in the treatment of neurodegenerative diseases have been developed for superoxide dismutase 1 (SOD1)-related ALS, Huntington’s disease, tauopathies, and Parkinson’s disease (Ghosh and Tabrizi, 2017). This evidence concerns the gene SOD1 and tauopathy.